The firm brought in $15.8 million during the quarter compared to $8.8 million a year ago, and beating Wall Street expectations.
The firm offered more than 2.7 million shares of its common stock, including 356,435 shares to its underwriters pursuant to an option to purchase additional shares.
The firm it plans to offer from time to time units of its common stock, preferred stock, one or more debt securities, warrants, or rights to such securities in one or more series.
The company missed the analysts' average estimates on the top and bottom lines, but it raised its full-year 2019 revenue guidance.
The companies will build clinical-genomic datasets to serve medical practitioners at the point of care as well as inform drug development.
Buoyed by a 26 percent increase in test volume, the firm's revenues were $1.2 million for the quarter, compared to $822,000 last year.
The team used this system to perform orthogonal and multiplexed genome engineering of endogenous targets using up to 25 individual CRISPR RNAs.
An analysis of more than 900 C. difficile isolates uncovered four phylogenetic lineages, including three lineages in a clade showing recent positive selection on infection-related genes.
Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
The company is delaying the publication of its business and financial update for the first half of 2019 to allow for an ongoing review by its auditors.
Onconova will use Mission Bio's Tapestri platform to study rigosertib — a drug that Onconova is developing — to target the RAS mutation in myelodysplastic syndromes.
Last week, GenomeWeb's readers were most interested in studies demonstrating the utility of 10x Genomics' platform to analyze immune cells in cancer therapies.
The firm said its platform provides sample-to-answer results for two of the most frequently tested sexually transmitted infections, enabling rapid testing and treatment.
Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.
Researchers analyzed more than 550 new and previously sequenced exomes for individuals from African rainforest hunter-gatherer and farming populations, searching for local adaptations.
Researchers compared gene expression patterns in the brains of people with and without schizophrenia to uncover differences in when genes were expressed.
The firm expects to use proceeds from the offering to expand its life sciences commercial operations, and improve and update its Simoa technology and instruments, among other initiatives.
The firm experienced a 30 percent jump in sales of immunoassays, attributed in part to a $6.2 million increase in influenza revenues year-over-year.
NantHealth's net loss fell by 37 percent, to $14.7 million, as revenue from software-related revenue jumped by 23 percent while expenses fell.
The San Diego-based genome mapping company attributed the drop in revenues to fewer international sales of its Saphyr platform.
Investigators saw signs that risky TP53 missense mutations may interfere with wild type copies of the tumor suppressor gene in acute myeloid leukemia and other myeloid cancers.
Researchers identified tumor microbe and immune differences in tumor samples from pancreatic ductal adenocarcinoma patients with exceptionally long survival.
Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.
ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.
The Washington Post reports that researchers are quickly analyzing the coronavirus that has been causing illness and sharing their findings.
In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.